Skip to main content
Top
Published in: Journal of Experimental & Clinical Cancer Research 1/2008

Open Access 01-12-2008 | Research

Histological vis – a – vis biochemical assessment on the toxic level and antineoplastic efficacy of a synthetic drug Pt – ATP on experimental animal models

Authors: Shipra Pal, Arpita Sengupta Sadhu, Swarup Patra, Kalyan K Mukherjea

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2008

Login to get access

Abstract

Background

Cisplatin, a platinum based anticancer drug has played a vital role in the treatment of cancers by chemical agents, but in view of the serious toxicity including nephrotoxicity of cisplatin, various other platinum based drugs have been synthesized and screened to overcome its toxicity. A Pt-ATP compound was prepared in our laboratory hoping to have reduced or no toxicity along with the potentiality of reducing neoplasm growth.

Methods

A Pt-ATP compound was prepared. It was first screened for its antineoplastic efficacy. Confirming that, subsequent experiments were carried on to test its toxicity on animals, viz. Albino Swiss mice. The animals were randomly divided into four sets – Set I: Erhlich Ascites Carcinoma (EAC) challenged mice; Set II: Normal mice; Set III: Drug treated mice, Set IVA Cisplatin (CDDP) treated mice, Set IV B EAC challenged Cisplatin treated mice. Set I was used to test antineoplasticity of the drug, Set II and Set III for studying drug toxicity and Set IV was treated with CDDP. Set II was used as a control. Animals were sacrificed after 5 days, 10 days 15 days and 20 days of drug administration on the 6th, 11th, 16th and 21st days respectively for Set I, II and III. Set IVA was sacrificed only on the 16th day and Set IV B on 6th and 11th days. For Set I only tumor cell count and packed cell volume (PCV) of tumor cells were recorded. For Set II and III, aspartate aminotransferase (AST), alanine aminotransferase (ALT) assays were done using serum while blood creatinine and creatine were assayed from blood filtrate. For cytotoxicity assessment liver, spleen and kidney tissues were collected and subjected to scanning electron microscopy (SEM) after extensive treatment. Set IV A was only studied for the biochemical parameters viz. aspartate aminotransferase (AST), alanine aminotransferase (ALT) assays were done using serum while blood creatinine and creatine were assayed from blood filtrate. Set IV B was studied for tumor cell count after treatment with CDDP for 10 days.

Results

Our comparative studies with normal and drug treated animals reveal that the drug does not affect the body weight of the drug treated animals significantly. The biochemical parameters like ALT and AST levels are also within normal limits which rules out hepatotoxicity. The detailed histological studies by SEM reveal that the hepatic, kidney and spleen tissues are not adversely affected by the drug. Comparison of biochemical parameters with the CDDP treated animals show that Pt-ATP is not at all toxic like the CDDP. The Kaplan-Meier analysis of the survival data of Set I has shown promising results with a significance of p < 0.0001.

Conclusion

Set I results are promising and indicating antineoplastic efficacy of the synthesized drug with increased life span of the animals. Biochemical analysis, hematological and SEM studies revealed that the drug was neither nephrotoxic nor hepato-spleeno-toxic under the experimental set up.
Appendix
Available only for authorised users
Literature
1.
go back to reference Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson JD: Cancer. Molecular biology of the cell. 1994, Third Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson JD: Cancer. Molecular biology of the cell. 1994, Third
2.
go back to reference Hofsh HP, Wagener DJT, De Valk-Bakker V, van Rennes H, De Vos D, Doesburg WH, Ottenheijm HCJ, De Grip WJ: Preclinical antitumor activity of ethyldeshydroxysparsomycin in combination with cisplatin. Invest New Drugs. 1995, 13 (1): 23-32. 10.1007/BF02614216.CrossRef Hofsh HP, Wagener DJT, De Valk-Bakker V, van Rennes H, De Vos D, Doesburg WH, Ottenheijm HCJ, De Grip WJ: Preclinical antitumor activity of ethyldeshydroxysparsomycin in combination with cisplatin. Invest New Drugs. 1995, 13 (1): 23-32. 10.1007/BF02614216.CrossRef
3.
go back to reference Eichorn LH, Donohue J: cis-Diamminedichloroplatinum, vinblastine and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med. 1977, 87 (3): 289-293. Eichorn LH, Donohue J: cis-Diamminedichloroplatinum, vinblastine and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med. 1977, 87 (3): 289-293.
4.
go back to reference Germa JR, Piera JM, Bernadas A, Badia J: Sequential combination chemotherapy for malignant germ cell tumors of ovary. Cancer. 1988, 61: 913-918. 10.1002/1097-0142(19880301)61:5<913::AID-CNCR2820610510>3.0.CO;2-9.CrossRef Germa JR, Piera JM, Bernadas A, Badia J: Sequential combination chemotherapy for malignant germ cell tumors of ovary. Cancer. 1988, 61: 913-918. 10.1002/1097-0142(19880301)61:5<913::AID-CNCR2820610510>3.0.CO;2-9.CrossRef
5.
go back to reference Merleno M, Grimaldi A, Brunetti I, Modenesi M, Scala M, Margarino G, Scasso F, Santelli A, Castiglia G: Simultaneous cisplatin and Flurouracil as second line treatment of head and neck cancer. Cancer Treat Rep. 1987, 71: 485-488. Merleno M, Grimaldi A, Brunetti I, Modenesi M, Scala M, Margarino G, Scasso F, Santelli A, Castiglia G: Simultaneous cisplatin and Flurouracil as second line treatment of head and neck cancer. Cancer Treat Rep. 1987, 71: 485-488.
6.
go back to reference Lee TK, Poon RTP, Wo JY, Ma S, Guan XY, Myer JN, Altevogt P, Yuen PW: Lupeol suppresses Cisplatin induced nuclear factor κB activation in head and neck squamous cell carcinoma and inhibits local invasion and nodal metastasis in an orthotopic nude mouse model. Cancer Res. 2007, 67: 8800-8809. 10.1158/0008-5472.CAN-07-0801.CrossRef Lee TK, Poon RTP, Wo JY, Ma S, Guan XY, Myer JN, Altevogt P, Yuen PW: Lupeol suppresses Cisplatin induced nuclear factor κB activation in head and neck squamous cell carcinoma and inhibits local invasion and nodal metastasis in an orthotopic nude mouse model. Cancer Res. 2007, 67: 8800-8809. 10.1158/0008-5472.CAN-07-0801.CrossRef
7.
go back to reference Chen MJ, Dumitrache LC, Wangsa D, Ma SM, Nash HP, Reid T, Nasty P: Cisplatin depletes TREX2 and causes Robertsonian translocation as seen in TREX 2 Knock out cells. Cancer Res. 2007, 67: 9077-9038. 10.1158/0008-5472.CAN-07-1146.CrossRef Chen MJ, Dumitrache LC, Wangsa D, Ma SM, Nash HP, Reid T, Nasty P: Cisplatin depletes TREX2 and causes Robertsonian translocation as seen in TREX 2 Knock out cells. Cancer Res. 2007, 67: 9077-9038. 10.1158/0008-5472.CAN-07-1146.CrossRef
8.
go back to reference Dronkert ML, Kanaar R: Repair of DNA interstrand crosslinks. Mutat Res. 2001, 486: 217-247.CrossRef Dronkert ML, Kanaar R: Repair of DNA interstrand crosslinks. Mutat Res. 2001, 486: 217-247.CrossRef
9.
go back to reference Szakacs G, Annereau JP, Lababidi S, Shankavaram U, Arciello A, Bussey KJ, Reinhold W, Guo Y, Kruh GD, Reimers M, Weinstein JN, Gottesman MM: Predicting drug sensitivityand resistance: profiling ABC transporter genes in cancer cells. Cancer Cell. 2004, 6: 129-137. 10.1016/j.ccr.2004.06.026.CrossRef Szakacs G, Annereau JP, Lababidi S, Shankavaram U, Arciello A, Bussey KJ, Reinhold W, Guo Y, Kruh GD, Reimers M, Weinstein JN, Gottesman MM: Predicting drug sensitivityand resistance: profiling ABC transporter genes in cancer cells. Cancer Cell. 2004, 6: 129-137. 10.1016/j.ccr.2004.06.026.CrossRef
10.
go back to reference Billecke C, Finniss S, Tahash L, Miller C, Mikkelsen T, Farrell NP, Bogler O: Polynuclear platinum anticancer drugs are more potent than cisplatin and induce cell cycle arrest in glioma. Neuro-oncol. 2006, 8: 215-226. 10.1215/15228517-2006-004.CrossRef Billecke C, Finniss S, Tahash L, Miller C, Mikkelsen T, Farrell NP, Bogler O: Polynuclear platinum anticancer drugs are more potent than cisplatin and induce cell cycle arrest in glioma. Neuro-oncol. 2006, 8: 215-226. 10.1215/15228517-2006-004.CrossRef
11.
go back to reference Trump DL, Grem JL, Tutsch KD, Willson JK, Simon KJ, Alberti D, Storer B, Tormey DC: Platinum and carboplatin. A phase – I trial with pharmacokinetic assessment of the effect of cisplatin administration on carboplatin excretion. J Clin Oncol. 1987, 5: 1281-1289. Trump DL, Grem JL, Tutsch KD, Willson JK, Simon KJ, Alberti D, Storer B, Tormey DC: Platinum and carboplatin. A phase – I trial with pharmacokinetic assessment of the effect of cisplatin administration on carboplatin excretion. J Clin Oncol. 1987, 5: 1281-1289.
12.
go back to reference Amer MH, Izdicki RM, Vaitkevicius VK, Al-Sarraf M: Combination chemotherapy with cis-diammine dichloroplatinum oncovin and bleomycin (COB) in advanced head and neck cancer, phaseII. Cancer. 1980, 45: 217-223. 10.1002/1097-0142(19800115)45:2<217::AID-CNCR2820450204>3.0.CO;2-8.CrossRef Amer MH, Izdicki RM, Vaitkevicius VK, Al-Sarraf M: Combination chemotherapy with cis-diammine dichloroplatinum oncovin and bleomycin (COB) in advanced head and neck cancer, phaseII. Cancer. 1980, 45: 217-223. 10.1002/1097-0142(19800115)45:2<217::AID-CNCR2820450204>3.0.CO;2-8.CrossRef
13.
go back to reference EL-Badawi MG, Amer MH, Dahaba NM, Fatani JA, Sabah DM, Mustafa FA: Histological changes following high dose methotrexate and cisplatin administration and the influence of dosage scheduling. Chemotherapy. 1987, 33: 278-286.CrossRef EL-Badawi MG, Amer MH, Dahaba NM, Fatani JA, Sabah DM, Mustafa FA: Histological changes following high dose methotrexate and cisplatin administration and the influence of dosage scheduling. Chemotherapy. 1987, 33: 278-286.CrossRef
14.
go back to reference Pal S, Mukherjea KK, Bhattacharya R, Maity P: Pt – ATP as antineoplastic agent in an experimental animal model system. J Exp Clin Cancer Res. 1997, 16: 255-60. Pal S, Mukherjea KK, Bhattacharya R, Maity P: Pt – ATP as antineoplastic agent in an experimental animal model system. J Exp Clin Cancer Res. 1997, 16: 255-60.
15.
go back to reference Mukherjea (Nayak) KK, Bhattacharya R, Maity P: Synthesis, characterization and in vitro cytotoxic effects of K4 (PtCl2 ATP). J Inorg Biochem. 1991, 41: 293-296. 10.1016/0162-0134(91)80022-A.CrossRef Mukherjea (Nayak) KK, Bhattacharya R, Maity P: Synthesis, characterization and in vitro cytotoxic effects of K4 (PtCl2 ATP). J Inorg Biochem. 1991, 41: 293-296. 10.1016/0162-0134(91)80022-A.CrossRef
16.
go back to reference Osser Bernard: Blood Analysis in Hawk's Physiological Chemistry. 641-14 Osser Bernard: Blood Analysis in Hawk's Physiological Chemistry. 641-14
Metadata
Title
Histological vis – a – vis biochemical assessment on the toxic level and antineoplastic efficacy of a synthetic drug Pt – ATP on experimental animal models
Authors
Shipra Pal
Arpita Sengupta Sadhu
Swarup Patra
Kalyan K Mukherjea
Publication date
01-12-2008
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2008
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-27-68

Other articles of this Issue 1/2008

Journal of Experimental & Clinical Cancer Research 1/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine